A nurse loads a syringe with a dose of Johnson & Johnson's COVID-19 vaccine in Athens, Ohio. Stephen Zenner/SOPA Images/LightRocket via Getty Images Johnson & Johnson shares climbed Wednesday after a European regulator found an overall benefit of the drug maker's COVID-19 vaccine. The European Medicines Agency did find a possible link between the vaccine and the 'rare' side effect of blood clots. J&J said it will resume shipment of its Janssen vaccine to the European Union. See more stories on Insider's business page. Johnson & Johnson shares pushed to a three-week high Tuesday, with the company restarting shipments of its COVID-19 vaccine to Europe after the European Union's drug agency said its benefits outweigh the potential risk of a "rare" side effect of blood clots.The European Medicines Agency said Tuesday it found a possible link between the company's vaccine and "very rare" cases of "unusual blood clots with low blood platelets."The agency said a warning should be added to product information about the Janssen-branded vaccine but also said the overall benefit-risk remains positive.Shares of Johnson & Johnson rose as much as 3.1% to trade above $167 each, marking their first time above that price since March 29.